<DOC>
	<DOCNO>NCT00651755</DOCNO>
	<brief_summary>The goal clinical research study learn effect combine aprepitant CHOP R-CHOP patient Non-Hodgkin 's Lymphoma ( NHL ) either newly diagnose come back . Researchers also want see aprepitant help prevent nausea and/or vomit may cause chemotherapy treatment CHOP R-CHOP , patient . CHOP consist four drug - Cyclophosphamide ( also call Cytoxan/Neosar ) , Doxorubicin ( Adriamycin ) , Vincristine ( Oncovin ) Prednisolone R-CHOP include Rituximab CHOP .</brief_summary>
	<brief_title>Aprepitant 's Effect Drug Metabolism Multi-Day Combination ( CHOP/R-CHOP ) Chemotherapy Regimen Lymphoma Patients</brief_title>
	<detailed_description>The Study Drugs : Aprepitant design block natural substance brain cause nausea vomit . This may help prevent and/or control nausea vomit cause cancer chemotherapy treatment . CHOP R-CHOP commonly use chemotherapy regimen treat NHL . In blood , aprepitant may increase decrease drug level cyclophosphamide , vincristine , and/or prednisone ( part CHOP R-CHOP regimen ) , know certain . This study design help researcher learn effect combine aprepitant CHOP R-CHOP . Study Groups : If find eligible take part study , randomly assign ( toss coin ) 1 2 group . There equal chance assign either group . Standard Chemotherapy Administration : Both CHOP R-CHOP typically 21-day `` cycle '' vary every 14 28 day . You receive CHOP R-CHOP accord schedule prescribe doctor . You also receive standard medication prevent nausea vomit . You sign separate consent form describe treatment detail , along risk . Aprepitant Administration : Aprepitant take mouth , without food . Group 1 take aprepitant Days 1 , 2 , 3 Study Cycle 1 . Group 2 take aprepitant Days 1 , 2 , 3 Study Cycle 2 . Study Diary : Prior study cycle , give study diary use throughout study . Once day , record side effect may experience . You bring study diary every study visit study staff review . Study Visits : Prior study cycle , study visit follow tests/procedures perform : - Your medical history record . - You physical exam , include measurement vital sign weight . - You performance status evaluation . - You fill questionnaire screening , nausea vomit may experience . - You ask medication may take . Be sure tell study doctor medication ( include vitamin , herbal product , nutritional supplement ) , medications/substances cause side effect take time aprepitant . - The study staff review study diary . Pharmacokinetic Testing : You additional blood sample draw pharmacokinetic ( PK ) test cyclophosphamide , vincristine , prednisone level . PK test measure amount drug body different time point . These PK blood draw 2 tablespoon . On Days 1 2 Study Cycles 1 2 , blood drawn PK test follow time : take prednisone , 30 minute start cyclophosphamide infusion , 60 minute , 75 minute , 90 minute , 2 , 4 , 6 , 8 , 24 hour start cyclophosphamide infusion . Other Blood Tests : At least twice week Study Cycles 1 2 , blood ( 1 teaspoon ) drawn routine test . Aprepitant may increase blood sugar first day drug take . Because , Day 1 Study Cycle 1 , give glucometer ( machine check blood sugar ) . You use glucometer home study ( hospital admit chemotherapy ) . You give instruction use , look . On Days 1-6 Study Cycle 1 , give `` fingerstick '' blood sugar test day ( breakfast ) . You take `` fingerstick '' blood sugar test receive dose aprepitant . Length Study : You may receive 2 cycle chemotherapy , include 1 cycle aprepitant . If intolerable side effect occur disease get bad , take study early . End-of-Study Visit : At 30 day last dose aprepitant , return end-of-study visit . At visit , tests/procedures perform study visit . You return glucometer study staff . This investigational study . The CHOP R-CHOP regimens commercially available FDA approve use NHL . Aprepitant commercially available FDA approve ( use combination nausea medication , ondansetron ) prevention nausea vomit may cause chemotherapy . However , study consider experimental researcher want find aprepitant may affect drug level cyclophosphamide , vincristine , prednisone blood . ( Cyclophosphamide , vincristine , prednisone part CHOP R-CHOP regimen . ) The use aprepitant authorize experimental purpose . Up 18 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>1 . Newly diagnose relapse lymphoid malignancy . 2 . Patients receive either : ( 1 ) Bolus 48hr infusion CHOP ( cyclophosphamide 750 mg/m^2 IV Day 1 , doxorubicin 25 mg/m^2/day IV give bolus infusion 48 hour continuous infusion Days 12 , vincristine 2 mg IV Day 1 , prednisone PO 100 mg * 5 day ) OR ( 2 ) Bolus 48hr infusion RCHOP ( Rituximab 375mg/m^2 Day 1+ CHOP ) . ( For patient receive RCHOP , CHOP may administer start Day 2 discretion treat physician 3 . Age &gt; /= 18 year 4 . Adequate organ function define serum total bilirubin &lt; /= 1.2 mg/dL , serum aspartate aminotransferase serum glutamate oxaloacetate transaminase ( SGOT ) &lt; /= 60 IU/L , creatinine &lt; 1.5 mg/dL . 1 . Evidence neoplastic central nervous system disease 2 . Patients unable take oral medication ( e.g . due tumor obstruction ) 3 . History Diabetes Mellitus ( Diabetes define establish diagnosis diabetes currently receive medication diabetes management and/or fast blood glucose &gt; /= 126 mg/dL . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Nausea</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>AD</keyword>
	<keyword>Hydroxydaunomycin hydrochloride</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Aprepitant</keyword>
	<keyword>Emend</keyword>
	<keyword>L754030</keyword>
	<keyword>MK869</keyword>
	<keyword>Drug Metabolism</keyword>
	<keyword>CHOP</keyword>
	<keyword>R-CHOP</keyword>
	<keyword>NHL</keyword>
</DOC>